QEL-005 / Quell Therap - LARVOL DELTA

QEL-005: A CD-19 Directed CAR Regulatory T cell Therapy for the Treatment of Complex Autoimmune Diseases Including Rheumatoid Arthritis and Systemic Sclerosis (EULAR 2026) - "QEL‑005 mediated antigen‑specific suppression of T cell proliferation in B cell–T cell co‑cultures and reversed the pro-inflammatory profile of IFNγ‑treated macrophages, accompanied by increased IL‑10 production and enhanced matrix metalloproteinase activity. Conclusions QEL‑005 CD19 CAR‑Tregs modulate multiple dysregulated cellular pathways relevant to RA and SSc and have the potential to restore tissue homeostasis in chronically inflamed environments."

Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology • Scleroderma • Systemic Sclerosis • CD80 • CD86 • FOXP3 • IFNG

QEL-005: A CD19 Directed CAR Regulatory T cell Therapy for Autoimmune Diseases Characterized by Multicellular Immune Dysregulation (FOCIS 2026) - "QEL-005 CD19 CAR-Tregs modulate several dysregulated cell types implicated in RA and SSc, demonstrating potential to re-establish tissue homeostasis in these diseases and in a broad spectrum of complex autoimmune diseases."

Fibrosis • Immunology • Inflammation • Inflammatory Arthritis • Rheumatoid Arthritis • Scleroderma • Systemic Sclerosis • CD80 • CD86 • FOXP3 • IFNG • IL10

QEL-005: A CD19 Directed CAR Regulatory T cell Therapy for Autoimmune Diseases Characterized by Multicellular Immune Dysregulation (FOCIS 2026) - No abstract available

Immunology

Study QEL-005-CLN-01. Phase I/II study of QEL-005 in patients with diffuse cutaneous systemic sclerosis (dcSSc) and in patients with difficult to treat rheumatoid arthritis (D2TRA). (clinicaltrialsregister.eu) - P1/2 | N=8 | Not yet recruiting | Sponsor: Quell Therapeutics Limited

First-in-human • New P1/2 trial • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology • Scleroderma • Systemic Sclerosis

CHILL: Controlling Hyperactive Immunity With Long-lived Lymphocytes (clinicaltrials.gov) - P1/2 | N=16 | Recruiting | Sponsor: Quell Therapeutics Limited | Not yet recruiting ➔ Recruiting

Enrollment open • First-in-human • Hematological Disorders • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology • Scleroderma • Systemic Sclerosis

CHILL: Controlling Hyperactive Immunity With Long-lived Lymphocytes (clinicaltrials.gov) - P1/2 | N=16 | Not yet recruiting | Sponsor: Quell Therapeutics Limited

First-in-human • New P1/2 trial • Hematological Disorders • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology • Scleroderma • Systemic Sclerosis

Quell Therapeutics Initiates CHILL Phase 1/2 Trial of Novel QEL-005 CAR-Treg Therapy in Refractory Rheumatoid Arthritis and Systemic Sclerosis Following UK CTA Approval (GlobeNewswire) - "CHILL is a multinational clinical study that will recruit up to 16 adult participants in the UK, Germany and Spain, with patient enrolment underway at leading clinical centres across the UK. Early clinical findings are expected during Q1 2027....Quell’s lead asset QEL-005, a pipeline-in-a-product for complex autoimmune diseases will be initiating clinical development in the Phase 1/2 CHILL clinical trial in H1 2026."

New P1/2 trial • P1/2 data • Rheumatoid Arthritis • Systemic Sclerosis

Quell Therapeutics to Unveil Promising Data for QEL-005, a Novel CAR-Treg Cell Therapy for Complex Autoimmune Diseases, at ACR Convergence 2025 (GlobeNewswire) - "Results from pre-clinical studies demonstrate immunomodulatory activity of QEL-005 across multiple immune cell lineages involved in complex autoimmune inflammation, including B cells, T cells and inflammatory macrophages....Data being presented supports CTA filings in Q4 ahead of initiating the CHILL clinical study in H1 2026 in patients with Rheumatoid Arthritis and Systemic Sclerosis."

New trial • Preclinical • Rheumatoid Arthritis • Systemic Sclerosis

QEL-005: CD19 CAR-Regulatory T cell therapy, a novel approach for the treatment of complex immune mediated inflammatory diseases including Rheumatoid Arthritis and Systemic Sclerosis (ACR Convergence 2025) - "In diseases such as RA and SSc with complex interactions of immune effector and tissue cell types, QEL-005 CD19 CAR-Tregs have the potential to durably restore homeostasis in chronically inflamed tissues with limited risk of drug associated toxicity."

IO biomarker • Immunology • Inflammation • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology • Scleroderma • Systemic Sclerosis • CD80 • FOXP3